Effect of peptide YY on pancreatico-biliary secretion in humans.
OBJECTIVE
The negative feedback on pancreatico-biliary secretion induced by ileal nutrients has been well documented but the role of the distal gut peptide YY (PYY) as mediator is less well defined. We determined the effect of PYY on basal, sham feeding and feeding-stimulated pancreatico-biliary secretion in humans.


METHODS
Eight healthy volunteers participated in a placebo-controlled, double-blind, randomized study with intravenous infusion of a physiological dose of PYY. Subjects were intubated with a naso-jejunal tube. Duodenal samples were aspirated continuously while a recovery marker perfused the duodenum. Outputs were measured in the basal state, in response to modified sham feeding (MSF) and during jejunal perfusion with a liquid meal. Blood samples were drawn for plasma cholecystokinin (CCK) and PYY measurements.


RESULTS
PYY infusion significantly (p<0.01) increased plasma PYY, from 16+/-2 to 55+/-6 pM. Basal outputs of amylase, lipase, trypsin and bilirubin were not affected by PYY. In the placebo experiment, MSF significantly increased amylase, lipase, trypsin and bilirubin outputs. However, during PYY infusion lipase, trypsin and bilirubin outputs did not significantly increase in response to MSF. Jejunal feeding, however, significantly (p<0.01) increased the outputs of bilirubin and enzymes equally during both the placebo and PYY infusions.


CONCLUSIONS
Infusion of PYY to physiological plasma levels exerts an inhibitory effect on pancreatico-biliary secretion during the cephalic phase of digestion, but not in the basal state or during the intestinal phase. PYY suppresses pancreatico-biliary secretion during the cephalic phase but not during the intestinal phase of nutrient digestion.
Symersky
Tomas
T
Department of Gastroenterology-Hepatology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Biemond
Izak
I
Frolich
Marijke
M
Masclee
Ad  A M
A
D000293:Adolescent; D000328:Adult; D000681:Amylases / Q000378:metabolism; D001663:Bilirubin / Q000378:metabolism; D002766:Cholecystokinin / Q000097:blood; D004063:Digestion / Q000187:drug effects / Q000502:physiology*; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005704:Gallbladder / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007441:Intubation, Gastrointestinal; D008875:Middle Aged; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D019894:Peptide YY / Q000493:pharmacokinetics / Q000494:pharmacology*; D011863:Radioimmunoassay; D012016:Reference Values; D013053:Spectrophotometry; D014357:Trypsin / Q000378:metabolism
D019894:Peptide YY; D002766:Cholecystokinin; D000681:Amylases; D014357:Trypsin; D001663:Bilirubin